Vinciane C.
- Country
- Belgium
- Department
- Oncology
Research Overview
- Evaluation of TAR-200 and Cetrelimab in Muscle-Invasive Urothelial Carcinoma of the Bladder Prior to Radical Cystectomy
- Phase 1/2 Evaluation of EPI-7386 and Enzalutamide Combination Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
- Phase II Randomized Study of Trastuzumab Deruxtecan vs. CDK4/6 Inhibitor-Based Endocrine Therapy in HR-Positive, HER2-Low/Ultra-Low Advanced Breast Cancer
Data & Insights
Has run more than one trial at 52 of 267 partner sites.
Specializations
Breast Cancer Research
This investigator specializes in treating ER-positive/HER2-negative early breast cancer, with particular focus on exploring innovative endocrine therapy approaches. Their research interests include extended adjuvant therapy and novel therapeutic interventions for hormone receptor-positive breast cancers.
- Endocrine-based therapeutic strategies
- Breast cancer recurrence prevention
- Novel therapeutic agents in breast cancer
Prostate Cancer Research
The investigator focuses on advanced treatments for metastatic castration-resistant prostate cancer. Their work encompasses combination therapy approaches and evaluation of novel anti-androgen treatments for patients who haven't previously received second-generation therapeutics.
- Combination therapy development
- Anti-androgen treatment strategies
- Advanced prostate cancer management
Bladder Cancer Research
The investigator conducts research in muscle-invasive urothelial carcinoma of the bladder, particularly focusing on patients who cannot receive traditional platinum-based treatments. Their work involves evaluating innovative therapeutic combinations and immunotherapy approaches.
- Novel bladder cancer therapeutics
- Alternative treatment pathways
- Pre-surgical therapeutic interventions
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.